Effect of antipsychotic replacement with quetiapine on the symptoms and quality of life of schizophrenic patients with extrapyramidal symptoms

Human Psychopharmacology

Volumn 21, Issue 7, 2006, Pages 439-445

  Taniguchi, Takahide ^a   Sumitani, Satsuki ^a   Aono, Michitaka ^a   Iga, Junichi ^a   Kinouchi, Sawako ^a   Aki, Hirosi ^a   Matsushita, Mami ^a   Taniguchi, Kyoko ^a   Tsuno, Mami ^a   Yamanishi, Kazunari ^a   Tomotake, Masahito ^a   Kaneda, Yasuhiro ^a   Ohmori, Tetsuro ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Quality of life; Quetiapine; Replacement; Schizophrenia

Indexed keywords

ANTIPARKINSON AGENT; CHLORPROMAZINE; GLUCOSE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADD ON THERAPY; ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HYPERGLYCEMIA; MALE; MEDICAL ASSESSMENT; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SCHIZOPHRENIA; SOMNOLENCE; SYMPTOM; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; DIBENZOTHIAZEPINES; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; QUESTIONNAIRES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33750520111     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.801     Document Type: Article

References (33)

1. Aki H, Tomotake M, Kaneda Y, et al. 2006. Subjective and objective quality of life, levels of life skills, and their clinical determinants I outpatients of schizophrenia. Psychiatry Res (in press).
2. Awad AG, Voruganti LN. 2004. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 18: 877-893.
3. Baldessarini RJ, Cohen BM, Teicher MH. 1988. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 45: 79-91.
4. Breier A, Buchanan RW, Irish D, Carpenter WT. 1993. Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. Hosp Community Psychiatry 44: 1145-1149.
5. Coryell W, Kelly M, Perry PJ, Miller DD. 1990. Haloperidol plasma levels and acute clinical change in schizophrenia. J Clin Psychopharmacol 10: 397-402.
6. Dickerson FB, Ringel NB, Parente F. 1998. Subjective quality of life in out-patients with schizophrenia: clinical and utilization correlates. Acta Psychiatr Scand 98: 124-127.
7. Emsley RA, Buckley P, Jones AM, Greenwood MR. 2003. Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia. J Psychopharmacol 17: 210-215.
8. Fitzgerald PB, Williams CL, Corteling N, et al. 2001. Subject and observer-rated quality of life in schizophrenia. Acta Psychiatr Scand 103: 387-392.
9. Franz M, Lis S, Pluddenmann K, Gallhofer B. 1997. Conventional versus atypical antipsychotics: subjective quality of life in schizophrenic patients. Br J Psychiatry 170: 422-425.
10. Heinrichs DW, Hanlon TE, Carpenter WT. 1984. The Quality of Life Scale: an instrument for rating the schizophrenic deficit symptoms. Schizophr Bull 10: 388-398.
11. Inada T. 1996. Evaluation and diagnosis of drug-induced extrapyramidal symptoms: commentary on the DIEPSS and guide to its usage. Seiwa Shoten: Tokyo.
12. Inagaki A, Inada T, Fujii Y, Yagi G, Yoshio T, Nakamura H, Yamauchi T. 1999. Equivalent doses of psychotropic drugs. Seiwa Shoten: Tokyo.
13. Kaneda Y, Ohmori T. 2003. Quetiapine impact on quality of life in patients with schizophrenia. Ann Pharmacother 37: 917-918.
14. Kaneda Y, Imakura A, Fujii A, Ohmori T. 2002. Schizophrenia quality of life scale: validation of the Japanese version. Psychiatry Res 113: 107-113.
15. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P. 2000. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 57: 553-559.
16. Kilian R, Dietrich S, Toumi M, Angermeyer MC. 2004. Quality of life in persons with schizophrenia in out-patient treatment with first- or second-generation antipsychotics. Acta Psychiatr Scand 110: 108-118.
17. Lambert M, Naber D. 2004. Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life. CNS Drugs 18(Suppl. 2): 5-17. discussion 41-43.
18. Meltzer HY, Burnett S, Bastani B, Ramirez LF. 1990. Effects of six months of clozapine treatment on the quality of life of chronic schizophranic patients. Hosp Community Psychiatry 41: 892-897.
19. Miyata R, Fujii Y. 1995. Quality of Life Scale Japanese Version. Seiwa Syoten: Tokyo.
20. Miyata R, Fujii Y, Inagaki A, Inada T, Yagi G. 1995. Reliability of the Japanese version of Brief Psychiatric Rating Scale (BPRS). Clin Eval 23: 357-367.
21. Mullen J, Jibson MD, Sweitzer D. 2001. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 23: 1839-1854.
22. Nemeroff CB, Kinkead B, Goldstein J. 2002. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry 63(Suppl. 13): S5-S11.
23. Overall JE, Gorham DR. 1962. The brief psychiatric rating scale. Psychol Rep 10: 799-812.
24. Revicki DA, Genduso LA, Hamilton SH, Ganoczy D, Beasley CM. 1999. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Qual Life Res 8: 417-426.
25. Ritsner M, Gibel A, Perelroyzen G, Kurs R, Jabarin M, Ratner Y. 2004. Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. J Clin Psychopharmacol 24: 582-591.
26. Rosenheck R, Cramer J, Xu W, et al. 1997. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med 337: 809-815.
27. Schulz SC, Thomson R, Brecher M. 2003. The efficacy of quetiapine vs. haloperidol and placebo: a meta-analytic study of efficacy. Schizophr Res 62: 1-12.
28. Seeman P, Tallerico T. 1998. Antipsychotic drugs which elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry 3: 123-134.
29. Tempier R, Pawliuk N. 2001. Influence of novel and conventional antipsychotic medication on subjective quality of life. J Psychiatry Neurosci 26: 131-136.
30. Velligan DI, Prihoda TJ, Sui D, Ritch JL, Maples N, Miller AL. 2003. The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. J Clin Psychiatry 64: 524-531.
31. Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A. 2000. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 43: 135-145.
32. Wilkinson G, Hesdon B, Wild D, et al. 2000. Self-report quality of life measure for people with schizophrenia: the SQLS. Br J Psychiatry 177: 42-46.
33. World Health Organization. 1992. The ICD-10 Classification of Mental and Behavioral Disorders: clinical descriptions and diagnostic guidelines.